Related Experiment Video

Updated: Apr 16, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

6.1K

Preclinical target validation using patient-derived cells

Aled M Edwards1, Cheryl H Arrowsmith2, Chas Bountra3

  • 1Structural Genomics Consortium, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada.

Nature Reviews. Drug Discovery
|February 28, 2015
PubMed

Insights

The Structural Genomics Consortium is launching open-source preclinical studies. These translational medicine initiatives involve clinical, industry, and disease-foundation partners.

Area of Science:

  • Biomedical Research
  • Translational Medicine
  • Drug Discovery

Background:

  • The Structural Genomics Consortium (SGC) facilitates research collaborations.
  • Preclinical research is crucial for advancing medical treatments.
  • Open-source approaches can accelerate scientific progress.

Purpose of the Study:

  • To launch novel open-source preclinical translational medicine studies.
  • To foster collaboration between academic, industry, and disease-foundation partners.
  • To accelerate the development of new therapies.

Main Methods:

  • Establishing collaborative research frameworks.
  • Implementing open-source data sharing protocols.
  • Coordinating preclinical study designs.

Main Results:

  • Initiation of multiple open-source preclinical studies.
  • Formation of a multi-sector consortium.
  • Development of shared research resources.

Conclusions:

  • Open-source preclinical studies can enhance translational medicine.
  • Partnerships across sectors are vital for drug development.
  • The SGC model promotes collaborative scientific advancement.

More Related Videos

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma12:16

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

21.9K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

Related Concept Videos

EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.5K